At the news
? NEUTRALIMPACT 3/10 6-K filed Jun 29, 2026 at 10:20 ET
Dodge & Cox, a top-3 institutional holder of GSK, disclosed a reduction in its voting rights stake from 5.01% to 4.96%, crossing below the 5% UK notification threshold. The sale of approximately 2 million shares (based on the 0.05% decline) is a modest trim by a long-term value manager, not a material bearish signal for a $107B pharma company.
- Dodge & Cox reduced its GSK voting rights stake from 5.01% to 4.96%, crossing below the 5% threshold on June 24, 2026.
- Total voting rights held: 201,065,668 (4.96% of total), split between ordinary shares (88,816,040; 2.19%) and ADRs (112,249,628; 2.77%).
- No financial instruments (options, swaps, etc.) were reported, the entire position is in common equity.
- Dodge & Cox remains a top-3 institutional holder per the 13F snapshot ($3.2B position as of Q1 2026).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access